Physician profile
Herschel E Stoller
NPI 1356324495
$9,828.82
in general payments reported to CMS, 2019-2025
29 companies · $1,500 in 2025
The $1,500 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,432 · 2020: $601 · 2021: $971 · 2022: $1,383 · 2023: $1,984 · 2024: $1,958 · 2025: $1,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,167 · Education: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,166.54 |
| Education | $275.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,848.79 | 2019-2025 | Skyrizi, Rinvoq |
| Amgen INC. | $1,486.61 | 2019-2025 | Otezla, Otezla, Enbrel |
| Janssen Biotech, INC. | $1,211.50 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Lilly USA, LLC | $855.15 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $607.69 | 2022-2025 | Sotyktu |
| Ucb, INC. | $467.38 | 2019-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $451.56 | 2019-2025 | Dupixent |
| Genzyme Corporation | $411.18 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $397.46 | 2019-2025 | Absorica Ld, Winlevi |
| Celgene Corporation | $377.34 | 2019 | |
| Dermavant Sciences, INC. | $286.25 | 2023-2024 | Vtama |
| Incyte Corporation | $220.58 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $188.21 | 2020-2025 | |
| Leo Pharma INC. | $178.08 | 2023-2025 | Adbry |
| Janssen Scientific Affairs, LLC | $124.92 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $116.17 | 2019-2020 | |
| Pfizer INC. | $109.77 | 2019-2023 | |
| Dermira, INC. | $84.68 | 2019-2020 | |
| Galderma Laboratories, L.P. | $78.14 | 2019-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $68.89 | 2023 | |
| Almirall LLC | $66.02 | 2022-2023 | Seysara |
| Botanix Sb INC | $53.24 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.20 | 2023 | Cyltezo |
| Sanofi-Aventis U.S. LLC | $24.42 | 2019 | |
| Mayne Pharma Commercial LLC | $21.12 | 2022 | |
| Promius Pharma LLC | $19.51 | 2019 | |
| Organon LLC | $18.49 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $15.21 | 2020 | |
| Nabriva Therapeutics, Plc | $14.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herschel Stoller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.